

1 **Temporal trends of dengue seroprevalence among children in coastal Kenya, 1998–2018: a**
2 **longitudinal cohort study**

3 Henry K. Karanja¹, Benedict Orindi¹, John N. Gitonga¹, Daisy Mugo¹, Kennedy Mwai¹, Doris K.
4 Nyamwaya¹, Donwilliams Omuoyo¹, Barnes S. Kitsao¹, Jennifer N. Musyoki¹, Julianna Wambua¹,
5 Edward Otieno^{1,2}, Lynette Isabella Ochola-Oyier¹, Philip Bejon^{1,2}, George M. Warimwe^{1,2}

6 ¹Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kenya;

7 ²Nuffield Department of Medicine, University of Oxford, UK

8

9 **Abstract**

10 Serosurveys suggest widespread dengue virus (DENV) transmission in Africa but there is limited
11 information on the temporal patterns of exposure. Here, we estimated the prevalence and incidence
12 of DENV infections in coastal Kenya over a 20-year period (1998–2018). Sera (n=8038) obtained
13 annually from a longitudinal cohort of 1847 children aged 15 years and below were screened for anti-
14 DENV IgG antibodies. Anti-DENV IgG seroprevalence increased with age and peaked during
15 outbreak years. Among 1354 children who were seronegative at recruitment, we observed an overall
16 incidence (seroconversion) rate of 129.5 (95% CI 118.7–141.4) DENV infections per 1000 person-
17 years. The highest incidence was observed in 2013 at 520 infections per 1000 person-years (95% CI
18 443.6–610.2) coinciding with a large DENV outbreak in coastal Kenya. Our data suggest long-term
19 DENV exposure among children in coastal Kenya highlighting an urgent need for clinical
20 surveillance to determine the associated health burden in this setting.

21

22 **Introduction**

23 Dengue virus (DENV) is the most widespread arbovirus globally, causing over 300 million infections

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
every year (*1*). This positive-stranded RNA virus belongs to the genus flavivirus and is composed of

25 a genome, approximately 11kb in size, that exists in four distinct serotypes (DENV-1 to DENV-4)
26 that can be further classified into multiple genotypes (2). Infection results in long-lived protection
27 against the infecting DENV serotype but only short-lived cross-protection against heterologous
28 serotypes (3). DENV is primarily transmitted by *Aedes aegypti* mosquitoes whose wide geographic
29 distribution accounts for the high global burden of the disease (4, 5). Most DENV infections are
30 asymptomatic, but an estimated 100 million clinical cases occur every year with manifestations
31 ranging from a mild self-limiting febrile illness to life-threatening symptoms such as hemorrhagic
32 fever and shock syndrome (2). Licensed dengue vaccines are now available for use in settings where
33 the disease is endemic (6, 7). Knowledge of the burden and geographic distribution of DENV
34 infections is essential for efficient deployment and use of dengue vaccines and other disease control
35 interventions.

36 The burden of DENV infections in Africa is poorly defined with most literature focusing on disease
37 outbreaks in Asia and the Americas (8). A modelling study suggests that Africa accounts for more
38 than 16% of the global burden of DENV infections annually (1). The limited seroprevalence and
39 outbreak report data available support widespread viral transmission on the continent (9), but there
40 are insufficient data on the age-specific risk of DENV exposure to inform local prioritization for
41 clinical surveillance and public health response. In Kenya, dengue outbreaks have been reported since
42 1982 with wide geographic risk of exposure (10-12). DENV-2 was implicated in the initial 1982
43 outbreak in coastal Kenya (10), and though other serotypes are in circulation (11-13), DENV-2 is
44 most frequently associated with outbreaks in Kenya and other settings in Africa (9, 14). For instance,
45 recent clinical surveillance in western and coastal Kenya during 2014 to 2017 identified a high
46 prevalence of DENV viraemia among children with undifferentiated fever (42% of 862 patients);
47 while viral genomes from all 4 DENV serotypes were detected, DENV-2 accounted for more than
48 half of the sequenced genomes (13). Together, these data suggest high levels of DENV exposure in
49 Kenya, but the extent to which exposure has varied over time remains unknown.

50 Here, we use a biobank to investigate the temporal trends of DENV exposure in coastal Kenya where
51 the bulk of DENV outbreaks in Kenya have been reported. We used immunoglobulin G (IgG) serology
52 to estimate the age-specific prevalence of anti-DENV IgG antibody among children aged between 6
53 months and 15 years over a 20-year period, that is, 1998 to 2018.

54

55 **Materials and methods**

56 **Study population**

57 This study was nested within an ongoing longitudinal cohort study at the Kenya Medical Research
58 Institute (KEMRI)-Wellcome Trust Research Programme in Kilifi, coastal Kenya conducted since
59 1998 to date with the main aim of describing malaria incidence and transmission in this area (15, 16).
60 Briefly, children resident in Junju and Ngerenya sub-locations within the Kilifi Health and
61 Demographic Surveillance System (KHDSS) (17) are recruited at birth and remain in the cohort until
62 the age of 15 years. The malaria surveillance has been running in Ngerenya since 1998 and in Junju
63 since 2005. Every year, a cross-sectional survey is conducted and includes blood sampling of cohort
64 participants and collection of demographic data. Sera (and linked demographic data) collected during
65 these annual cross-sectional surveys were available at the KEMRI-Wellcome Trust Research
66 Programme biobank, allowing an assessment of DENV seroprevalence over time. Ethical approval
67 was provided by the KEMRI Scientific and Ethics Review Unit (KEMRI SERU # 3296, #1131).

68 **Estimation of DENV exposure by serology**

69 We measured anti-DENV IgG antibodies by enzyme-linked immunosorbent assay (ELISA) against
70 a local DENV-2 isolate obtained from a patient in the same geographic setting (18). DENV-2 was
71 selected for this assay owing to its frequent circulation in Kenya and ready availability of DENV-2
72 virus in our lab (13, 19, 20). Briefly, 96 wells Maxisorp flat-bottomed plates were coated with 50µL
73 of $\sim 1 \times 10^3$ TCID₅₀ whole DENV-2 virus lysate per well and incubated for 1 hour at room temperature
74 (RT), fixed with 4% paraformaldehyde for 30 minutes at RT and blocked with Blocker™ Casein in

75 Phosphate Buffered Saline (PBS) (ThermoScientific, cat. # 37528). Serum samples were diluted
76 1:500 in Blocker™ Casein and added to the DENV-coated plates and incubated for 2 hours at 37°C.
77 The plates were washed 3 times with wash buffer (0.1% Tween20 in PBS), after which 1:10000
78 dilution of Peroxidase Labelled Goat Anti-Human IgG (Cat. # 074-1002, KPL) in wash buffer was
79 added to the plates and incubated for one hour. After another series of washes, the plates were
80 developed by adding 100µL/well of reconstituted o-phenylenediamine dihydrochloride (Sigma, cat.
81 # 8287) for 15–20 minutes and the reaction stopped by adding 100µl/well of 2NH₂SO₄. Colour
82 reaction was measured at 492nm by the Tecan Infinite® 200 PRO. Each plate included serial dilutions
83 of a pooled sera sample from six Kenyan adults with high virus neutralising antibody titres against
84 DENV-2 from which a standard curve was generated and used to extrapolate IgG responses
85 (expressed as ELISA units) for each test sample. To define a seropositivity cut-off we used the whole
86 virus IgG ELISA to test sera from 108 adults with corresponding focus reduction neutralisation test
87 (FRNT₉₀) data (18) and determined the sensitivity and specificity of the IgG ELISA in detecting
88 DENV-2 FRNT₉₀ positive sera. An IgG ELISA unit cut-off ≥ 250 had a specificity of 91.1% and
89 sensitivity of 92.1% in identifying individuals with DENV-2 neutralising antibodies as measured by
90 FRNT₉₀ assay and was therefore used for the analysis presented herein. Because IgG ELISA cannot
91 reliably distinguish DENV serotype-specific responses (2), which requires use of the highly specific
92 virus neutralisation assays, we describe the IgG immune responses as anti-DENV rather than anti-
93 DENV-2.

94 **Statistical analysis**

95 First, we estimated DENV seroprevalence, together with the associated 95% Agresti-Coull
96 confidence interval by sex, age, location of residence (Junju or Ngerenya) and year of sampling. Next,
97 to assess whether the seroprevalence varied with sex, age, location and year we fitted a mixed-effects
98 logistic regression model, with child as a random effect. Age entered the model as a linear spline
99 function with a single knot at 10 years (21), such that we estimated the linear effect of age up to the
100 age of 10 years then the linear effect of age after 10 years. The covariates were tested using the

101 likelihood ratio (LR) test. Finally, we estimated incidence rates (IR) of DENV infection (defined as
102 IgG seropositivity in the whole virus ELISA) among children and compared across variables using
103 Poisson regression, with the logarithm of person-years as offset. This analysis only included children
104 who were initially DENV seronegative at recruitment, and children were censored after their first
105 DENV infection (that is, when they turned IgG seropositive). We report incidence rates per 1000
106 person-years. Data were analysed using Stata version 17.0 (StataCorp, College Station, TX) and
107 graphs generated using GraphPad Prism version 9.5.1 (GraphPad Software, San Diego, California
108 USA). All tests were performed at 0.05 significance level.

109

110 **Results**

111 A total of 8038 serum samples obtained from 1847 children at annual cross-sectional surveys
112 between 31st August 1998 and 10th April 2018 were available in the KEMRI-Wellcome Trust
113 Research Programme biobank. The median number of annual cross-sectional surveys (or years of
114 follow-up) for the 1847 children was 2 (range 1–14), contributing to a total of 7394.2 years of
115 follow-up over the 20-year period. The median age of the children over the entire follow-up period
116 was 7.1 years (interquartile range 4.1–10.3). Of the 8038 serum samples 3965 (49.3%) came from
117 children resident in Junju and 4073 (50.7%) were from residents of Ngerenya (Table 1).

118 Overall, 2295 (28.6%, 95% CI 27.6–29.5%) of the 8038 samples were seropositive for DENV IgG
119 antibodies. However, DENV seroprevalence markedly increased with age from a low of 2.2%
120 among children aged below 1 year to a high of 40% among those aged 9 and 10 years (Odds ratio
121 (OR) 1.46, 95% CI 1.40–1.52; $p < 0.001$), after which the seroprevalence remained the same (OR
122 0.97, 95% CI 0.92–1.03) (Figure 1C and Table 1). DENV seroprevalence varied substantially over
123 the years (LR test $p < 0.0001$) with seroprevalence as high as 60% observed in 1998 and 2013, to a
124 low of approximately 12% in 2017 (Figure 1A) but did not vary significantly by sex ($p = 0.438$) and
125 location ($p = 0.834$) (Table 1).

126 During the 20-year period, we observed 503 new DENV infections (i.e., seroconversion among 1354
127 participants who were seronegative at recruitment), giving an overall incidence rate of 129.2 (95%
128 CI 118.4–141.0) DENV infections per 1000 person-years. The incidence of seroconversion did not
129 vary by sex (incidence rate ratio (IRR) 1.02, 95% CI 0.85–1.21; $p=0.841$) and geographical location
130 of residence ($p=0.365$), but it linearly increased with age at the rate of 5% per one year increase in
131 age up to around the age of 9–10 years (IRR 1.05, 95% CI 1.01–1.10; $p=0.019$) (Table 1 and Figure
132 1D). The highest incidence of seroconversion was observed in 2013 at 520 cases per 1000 person-
133 years (95% CI 443.6–610.2), followed by 2008 at 182.3 cases per 1000 person-years (95% CI 130.9–
134 253.9) and 2011 at 174.8 cases per 1000 person-years (95% CI 137.8–221.7) (Figure 1B; LR test
135 $p<0.001$).

136

137 **DISCUSSION**

138 There is limited surveillance for DENV in Africa beyond sporadic reporting of outbreaks (22). The
139 true burden of DENV infections therefore remains unknown with modelling studies suggesting a
140 burden in Africa that is at least as high as that in Latin America (1). Most of the previous serological
141 assessments of DENV exposure in Africa have tended to be cross-sectional in nature, providing
142 information on the geographical extent of DENV transmission but limited information on the
143 temporal dynamics of viral exposure (14). Our data provide a two-decade assessment of DENV
144 infections in coastal Kenya.

145 We confirm high levels of DENV exposure in coastal Kenya, in keeping with previous serological
146 studies and outbreak reports (11, 12, 18). DENV seropositivity showed a positive relationship with
147 age suggesting ongoing endemic transmission in this setting. Seropositivity peaked in 1998–2000 and
148 2013, coinciding with periods when DENV cases were reported in neighbouring countries (Tanzania
149 and Uganda in 1999–2000 (14)) and with one of the largest DENV outbreaks in coastal Kenya
150 reported in 2013 (23). During the 2013 outbreak, DENV cases were predominantly reported in

151 Mombasa (23). However, the very high incidence of DENV seroconversion observed in Kilifi,
152 approximately 50km north of Mombasa, during this period suggests that the outbreak was more
153 widespread along the Kenyan coast than previously thought (11). We also detected high incidence of
154 DENV seroconversion during 2008 and 2011, coinciding with a confirmed DENV outbreak in
155 northern Kenya and neighbouring Somalia in 2011 (24), and a possible undetected outbreak in 2008
156 in coastal Kenya. These incidence data support the utility of serology in inferring exposure to DENV
157 infections.

158 DENV-2 has been implicated in most outbreaks and case reports in Africa, but other DENV serotypes
159 are increasingly being detected during outbreaks, including importations from Asia (9, 14). Increasing
160 circulation of multiple DENV serotypes is of public health concern due to the potential for severe
161 disease associated with serial infection with heterologous DENV serotypes (25). Two types of
162 immune responses are elicited by infection: a long-lived protective antibody response against the
163 infecting DENV serotype and a short-lived cross-reactive response against other (heterologous)
164 DENV serotypes (2, 3). During subsequent infection(s) with a heterologous DENV serotype, these
165 cross-reactive weaker antibody responses are unable to neutralize virus infection but instead facilitate
166 Fc-mediated virus entry into host cells (e.g. monocytes) allowing the virus to thrive whilst evading
167 other host anti-viral defenses, resulting in enhanced pathology that underlies severity disease (2, 25).
168 Our assay could not distinguish DENV serotype-specific responses. However, the high levels of
169 DENV exposure observed indicate an urgent need for long-term systematic clinical and
170 immunological surveillance to characterise DENV infections in this setting, the associated symptoms
171 and outcomes, and the predisposing risk factors. All four DENV serotypes have been associated with
172 febrile illness in children in Kenya (13), but interestingly, the current WHO clinical diagnostic criteria
173 for dengue performed poorly in this setting with no severe complications observed (26). This further
174 highlights a need for development of clinical algorithms that can identify patients with DENV
175 infection in East Africa, both for clinical diagnosis and for use in evaluation of disease control
176 interventions.

177 This study had limitations. First, we used whole DENV-2 virus for the detection of circulating IgG
178 antibodies and while assay performance was good in comparison to virus neutralising responses, the
179 assay cannot distinguish DENV serotype-specific responses and it is likely there were cross-reactive
180 responses against other DENV serotypes and related flaviviruses (e.g., Zika virus). The relative
181 contribution of the four DENV serotypes to the observed exposure levels could therefore not be
182 determined. Nevertheless, we could detect incident cases during periods when DENV outbreaks were
183 reported in Kenya (23), and our previous work suggests limited circulation of Zika virus in the study
184 location (18). Second, this study provides an unprecedented 20-year longitudinal assessment of
185 DENV exposure in coastal Kenya. While this has allowed a long-term view of exposure trends, the
186 limited geographical focus precludes generalisation to other settings in the country and the region.
187 However, previous dengue outbreaks have tended to involve multiple countries in East Africa, and
188 the shared ecology supportive of the *Aedes spp* and other mosquito vectors suggests DENV infections
189 (as with other arboviruses) may be widespread in the region (8, 27, 28). Finally, we did not monitor
190 clinical illness and therefore could not determine what fraction of the observed exposures had
191 experienced symptomatic infections. With licensed dengue vaccines now available (6, 7), an
192 assessment of the disease burden in Kenya and other African countries is urgently needed to inform
193 decisions on vaccine deployment and use.

194

195 **Acknowledgements**

196 This work was funded by Wellcome Trust grant (grant number 203077_Z_16_Z to PB) and an Oak
197 Foundation fellowship to GMW. The funders had no role in study design, data collection and analysis,
198 decision to publish, or preparation of the manuscript.

199

200 **References**

201 1. S. Bhatt *et al.*, The global distribution and burden of dengue. *Nature* **496**, 504-507 (2013).

- 202 2. A. Wilder-Smith, E. E. Ooi, O. Horstick, B. Wills, Dengue. *Lancet* **393**, 350-363 (2019).
- 203 3. W. M. Wahala, A. M. Silva, The human antibody response to dengue virus infection.
204 *Viruses* **3**, 2374-2395 (2011).
- 205 4. O. J. Brady, S. I. Hay, The Global Expansion of Dengue: How *Aedes aegypti* Mosquitoes
206 Enabled the First Pandemic Arbovirus. *Annu Rev Entomol* **65**, 191-208 (2020).
- 207 5. M. U. Kraemer *et al.*, The global distribution of the arbovirus vectors *Aedes aegypti* and *Ae.*
208 *albopictus*. *Elife* **4**, e08347 (2015).
- 209 6. S. Biswal *et al.*, Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and
210 Adolescents. *N Engl J Med* **381**, 2009-2019 (2019).
- 211 7. M. R. Capeding *et al.*, Clinical efficacy and safety of a novel tetravalent dengue vaccine in
212 healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
213 *Lancet* **384**, 1358-1365 (2014).
- 214 8. E. M. Gainor, E. Harris, A. D. LaBeaud, Uncovering the Burden of Dengue in Africa:
215 Considerations on Magnitude, Misdiagnosis, and Ancestry. *Viruses* **14**, (2022).
- 216 9. G. O. Mwanyika *et al.*, Dengue Virus Infection and Associated Risk Factors in Africa: A
217 Systematic Review and Meta-Analysis. *Viruses* **13**, (2021).
- 218 10. B. K. Johnson, S. Musoke, D. Ocheng, A. Gichogo, P. H. Rees, Dengue-2 virus in Kenya.
219 *Lancet* **2**, 208-209 (1982).
- 220 11. L. Konongoi *et al.*, Detection of dengue virus serotypes 1, 2 and 3 in selected regions of
221 Kenya: 2011-2014. *Virol J* **13**, 182 (2016).
- 222 12. E. M. Muthanje *et al.*, March 2019 dengue fever outbreak at the Kenyan south coast
223 involving dengue virus serotype 3, genotypes III and V. *PLOS Glob Public Health* **2**,
224 e0000122 (2022).
- 225 13. M. M. Shah *et al.*, High Dengue Burden and Circulation of 4 Virus Serotypes among
226 Children with Undifferentiated Fever, Kenya, 2014-2017. *Emerg Infect Dis* **26**, 2638-2650
227 (2020).

- 228 14. A. Amarasinghe, J. N. Kuritsk, G. W. Letson, H. S. Margolis, Dengue virus infection in
229 Africa. *Emerg Infect Dis* **17**, 1349-1354 (2011).
- 230 15. T. W. Mwangi, A. Ross, R. W. Snow, K. Marsh, Case definitions of clinical malaria under
231 different transmission conditions in Kilifi District, Kenya. *J Infect Dis* **191**, 1932-1939
232 (2005).
- 233 16. A. Olotu *et al.*, Defining clinical malaria: the specificity and incidence of endpoints from
234 active and passive surveillance of children in rural Kenya. *PLoS One* **5**, e15569 (2010).
- 235 17. J. A. Scott *et al.*, Profile: The Kilifi Health and Demographic Surveillance System
236 (KHDSS). *Int J Epidemiol* **41**, 650-657 (2012).
- 237 18. H. C. Barsosio *et al.*, Congenital microcephaly unrelated to flavivirus exposure in coastal
238 Kenya. *Wellcome Open Res* **4**, 179 (2019).
- 239 19. E. Kamau *et al.*, Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi,
240 Kenya. *Microbiol Resour Announc* **8**, (2019).
- 241 20. M. M. Masika *et al.*, Detection of dengue virus type 2 of Indian origin in acute febrile
242 patients in rural Kenya. *PLoS Negl Trop Dis* **14**, e0008099 (2020).
- 243 21. N. A. Schuster, J. J. M. Rijnhart, J. W. R. Twisk, M. W. Heymans, Modeling non-linear
244 relationships in epidemiological data: The application and interpretation of spline models.
245 *Front. Epidemiol.*, (2022).
- 246 22. T. Jaenisch *et al.*, Dengue expansion in Africa-not recognized or not happening? *Emerg*
247 *Infect Dis* **20**, (2014).
- 248 23. E. M. Ellis *et al.*, A household serosurvey to estimate the magnitude of a dengue outbreak in
249 Mombasa, Kenya, 2013. *PLoS Negl Trop Dis* **9**, e0003733 (2015).
- 250 24. M. Obonyo, A. Fidhow, V. Ofula, Investigation of laboratory confirmed Dengue outbreak in
251 North-eastern Kenya, 2011. *PLoS One* **13**, e0198556 (2018).
- 252 25. S. B. Halstead, Neutralization and antibody-dependent enhancement of dengue viruses. *Adv*
253 *Virus Res* **60**, 421-467 (2003).

- 254 26. A. Khan *et al.*, Majority of pediatric dengue virus infections in Kenya do not meet 2009
255 WHO criteria for dengue diagnosis. *PLOS Glob Public Health* **2**, e0000175 (2022).
- 256 27. A. A. Bettis *et al.*, The global epidemiology of chikungunya from 1999 to 2020: A
257 systematic literature review to inform the development and introduction of vaccines. *PLoS*
258 *Negl Trop Dis* **16**, e0010069 (2022).
- 259 28. K. N. Gerken *et al.*, Paving the way for human vaccination against Rift Valley fever virus:
260 A systematic literature review of RVFV epidemiology from 1999 to 2021. *PLoS Negl Trop*
261 *Dis* **16**, e0009852 (2022).

262

263 **Table 1. Prevalence and incidence rates of DENV infection among children in Kilifi by sex, age and location**

	Number of children	Number of samples	Samples positive	Seroprevalence			Person years*	Incidence			
				% positive (95% CI)	Adjusted odds ratio (95% CI)	P-value		Cases	Incidence rate/1000 person-years (95% CI)	Incidence rate ratio (95% CI)	P-value
Overall	1847	8038	2295	28.6 (27.6–29.5)			3893.2	503	129.2 (118.4–141.0)		
Sex											
Female	900	3849	1089	28.3 (26.9–29.7)	Reference		1875.2	239	127.5 (112.3–144.7)	Reference	
Male	947	4189	1206	28.8 (27.4–30.2)	1.10 (0.87–1.38)	0.438	2018.0	264	130.8 (116.0–147.6)	1.02 (0.85–1.21)	0.841
Age in years**											
Age spline 1					1.46 (1.40–1.52)	<0.001				1.05 (1.01–1.10)	0.019
Age spline 2					0.97 (0.92–1.03)	0.310				0.98 (0.90–1.106)	0.564
Location											
Junju	907	3965	1019	25.7 (24.4–27.1)	Reference		1680.9	249	148.1 (130.8–167.7)	Reference	
Ngerenya	940	4073	1276	31.3 (29.9–32.8)	0.97 (0.73–1.29)	0.834	2212.2	254	114.8 (101.5–129.8)	0.91 (0.74–1.12)	0.365


264

265 *Person-years contributed by the 1847 children up to the point of their first DENV infection detection, beyond which children were censored.

266 **Non-linear age effect was modelled using a 1-knot linear spline. Age spline 1 represent the continuous age measurements in the range 0.5 to 10; age spline 2 represent the

267 continuous age measurements in the range 10–15 years. Age splines 1 and 2 estimate the linear effect of age in those two age ranges.

268 **Figure 1. Prevalence and incidence of DENV IgG antibodies by year of sampling and age of**
269 **the children**



270

271 Presented in (A) are the percentages of children with anti-DENV IgG antibodies in each annual cross-
272 sectional survey during the study period. In (B) the incidence of anti-DENV IgG seroconversion
273 among children who were seronegative for DENV at recruitment is shown over time. (C) presents the
274 percentages of children with anti-DENV IgG antibodies from 1998–2018 by 1-year age bands. (D)
275 presents the incidence of anti-DENV IgG seroconversion among children who were seronegative for
276 DENV at recruitment by 1-year age bands. An incidence estimate could not be made for the year
277 1998 and for children aged below 1 year as participants did not have a positive time at risk. The bold
278 arrows indicate when dengue outbreaks occurred in Kenya (solid) and in neighbouring countries
279 (dashed).

280

281